Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early vs Standard Zoledronic Acid in Metastatic Prostate Cancer
NCT00079001Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jan 2004
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Zoledronic acid + ADT with Placebo + ADT (2 arms). Primary endpoint: Time to First Skeletal Related Event up to 10 years. Started Jan 2004; status: completed.
02
Drugs
zoledronic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00079001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00079001.